Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
171.56M | 167.51M | 119.73M | 101.83M | 99.38M | Gross Profit |
133.99M | 125.66M | 86.15M | 74.91M | 71.09M | EBIT |
9.12M | 18.00M | 792.00K | 8.38M | 11.66M | EBITDA |
21.72M | 29.50M | 7.86M | 15.75M | 16.70M | Net Income Common Stockholders |
12.97M | 19.88M | 3.74M | 8.58M | 10.14M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
129.55M | 112.16M | 94.51M | 96.03M | 91.78M | Total Assets |
237.34M | 226.07M | 193.24M | 164.57M | 148.23M | Total Debt |
9.30M | 10.72M | 11.71M | 2.49M | 2.61M | Net Debt |
-120.25M | -101.44M | -82.80M | -93.54M | -89.17M | Total Liabilities |
55.14M | 62.22M | 54.55M | 29.01M | 24.00M | Stockholders Equity |
182.20M | 163.86M | 138.69M | 135.57M | 124.23M |
Cash Flow | Free Cash Flow | |||
20.27M | 19.74M | -271.00K | 5.93M | 20.83M | Operating Cash Flow |
22.78M | 23.31M | 6.70M | 7.32M | 22.76M | Investing Cash Flow |
-2.36M | -3.54M | -6.90M | -1.38M | -1.94M | Financing Cash Flow |
-3.01M | -2.71M | -1.97M | -1.03M | -1.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | AU$101.04M | 9.57 | 11.40% | 4.00% | 0.82% | 31.36% | |
75 Outperform | AU$111.04M | 11.17 | 23.38% | ― | 63.10% | 290.00% | |
69 Neutral | $1.32B | 78.75 | 9.23% | ― | 10.79% | 5.20% | |
54 Neutral | AU$177.62M | ― | -4.06% | ― | 15.90% | 8.52% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
45 Neutral | AU$112.00M | ― | -24.66% | ― | 0.70% | -1600.91% | |
44 Neutral | AU$116.69M | ― | -35.20% | ― | 4.68% | -155.42% |
Nanosonics Limited responded to a query from the Australian Securities Exchange (ASX) regarding unusual trading activity in its securities. The company stated that it is not aware of any undisclosed information that could explain the recent price and volume changes and confirmed compliance with ASX Listing Rules, particularly Rule 3.1, which pertains to continuous disclosure obligations.
The most recent analyst rating on (AU:NAN) stock is a Sell with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced a change in the director’s interest, with CEO Michael Kavanagh selling 100,000 ordinary shares to cover a tax liability from exercising company securities. Despite the sale, Kavanagh retains a significant holding of 1,256,723 shares and 1,569,840 rights, indicating continued confidence in the company’s prospects.
Nanosonics Limited announced that ECP Asset Management Pty Ltd and EC Pohl & Co Pty Ltd have ceased to be substantial holders in the company as of March 21, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market positioning, potentially affecting investor perceptions and stakeholder interests.
Nanosonics Limited has received FDA De Novo clearance for its CORIS® system, a novel technology aimed at reducing infection risks and improving cleaning outcomes for flexible endoscopes. This clearance marks a significant milestone for the company, with plans for a commercial launch in Q1 FY26, initially targeting a controlled market release in select hospitals before a broader rollout.
Nanosonics Limited announced a change in the director’s interest, with Gerard Dalbosco acquiring 7,442 ordinary shares, bringing his total to 27,442 shares. This transaction, valued at $32,372.70, reflects continued confidence in the company’s market position and potential growth, potentially impacting stakeholders’ perception positively.
Nanosonics Limited has announced the application for quotation of 43,298 ordinary fully paid securities on the Australian Securities Exchange. This move is part of an employee incentive scheme and indicates the company’s ongoing efforts to incentivize its workforce, potentially impacting its operational dynamics and market position positively.
Nanosonics Limited announced a change in the director’s interest notice due to an acquisition of performance rights by CEO Michael Kavanagh. The company acknowledged a delay in lodging the notice due to an administrative oversight and has since reviewed its procedures to ensure compliance with ASX listing rules.
Nanosonics Limited has issued an update to a previous announcement regarding the classification of securities. Initially reported as ordinary fully paid shares due to a selection error, the correct classification is NANAO Performance Rights, with 2,248,299 rights issued under the Nanosonics Employee Equity Plan. This correction clarifies the nature of the securities involved, which may impact stakeholders’ understanding of the company’s equity structure.
Nanosonics Limited has announced a change in the director’s interest, with Gerard Dalbosco acquiring 20,000 ordinary shares in the company. This acquisition, valued at approximately $87,139.75, reflects a significant investment by the director, potentially indicating confidence in the company’s future performance and strategic direction.